Point72 (DIFC)’s Y-mAbs Therapeutics YMAB Stock Holding History

Point72 (DIFC)’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-287	Closed	-$1.29K	–	1969
2025 Q2	$1.29K	Sell	287 -4,771	-94%	-$21.4K	﹤0.01%	1430
2025 Q1	$22.4K	Buy	5,058 +4,570	+936%	+$26.5K	﹤0.01%	1336
2024 Q4	$3.82K	Buy	+488	New	+$5.94K	﹤0.01%	1402
2024 Q3	–	Sell	-53	Closed	-$637	–	1894
2024 Q2	$637	Sell	53 -14,711	-100%	-$199K	﹤0.01%	1404
2024 Q1	$240K	Buy	+14,764	New	+$199K	0.01%	916

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 (DIFC)'s YMAB Position: Q3 2025 in Review

Point72 (DIFC) sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 287 shares — an estimated $1.29K sold.

Point72 (DIFC) first reported a position in YMAB in Q1 2024 and held it in 5 quarters. The position peaked at $240K in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Point72 (DIFC) reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Point72 (DIFC) sold 287 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.29K.
Point72 (DIFC) first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 5 quarters.
Point72 (DIFC)'s Y-mAbs Therapeutics position peaked at $240K in Q1 2024.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.